SCHEMBL648833

SCHEMBL648833

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CCNC(c1ccc2c(c1)OCO2)c1ccc2c(c1)OCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.40
ALPG P10696 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGFR P43088 2/20 0.37
TSHR P16473 1/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
ADORA2B P29275 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
DHODH Q02127 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767009 0.92 C5AR1 (0.57) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL650122 0.84 C5AR1 (0.49) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL6631217 0.84 C5AR1 (0.63) C5AR1SMN1; SMN2LMNAL3MBTL1ALDH1A1
SCHEMBL649603 0.84 C5AR1 (0.49) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL648839 0.83 C5AR1 (0.49) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL651123 0.83 C5AR1 (0.60) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL649207 0.83 C5AR1 (0.49) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL648795 0.82 C5AR1 (0.47) C5AR1SMN1; SMN2LMNAL3MBTL1USP2
SCHEMBL4765728 0.82 C5AR1 (0.45) C5AR1SMN1; SMN2L3MBTL1USP2ALPG
SCHEMBL649051 0.82 C5AR1 (0.47) C5AR1SMN1; SMN2LMNAL3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-09-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators C3AR1, C5AR1, C5AR2 C5AR1 2/4885SMN1; SMN2 4667/4885LMNA 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.